Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL128169 | 0.94 | — | — | |
| SCHEMBL8596055 | 0.94 | CA2 (0.58) | — | |
| SCHEMBL246838 | 0.94 | CA2 (0.58) | — | |
| SCHEMBL25599 | 0.94 | CA2 (0.58) | — | |
| SCHEMBL15109974 | 0.94 | — | — | |
| SCHEMBL105 | 0.94 | — | — | |
| SCHEMBL1448991 | 0.89 | — | — | |
| SCHEMBL22581619 | 0.89 | — | — | |
| SCHEMBL1774909 | 0.89 | — | — | |
| SCHEMBL21641627 | 0.89 | CA2 (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110507646-A | Application of the artemisinin derivative in the drug of preparation antianxiety disease or the food of alleviation anxiety disorder | UNIV GUANGZHOU CHINESE MEDICINE | 2019-11-29 | — | — | CN | disclosed |
| CN-110464721-A | Application of the artemisinin derivative in the drug or dormancy-aid food of preparation treatment insomnia | UNIV GUANGZHOU CHINESE MEDICINE | 2019-11-19 | — | — | CN | disclosed |
| CN-110446716-A | Process for the preparation of 2-exo- (2-methylbenzyloxy) -1-methyl-4-isopropyl-7-oxabicyclo [2.2.1] heptane | BASF AGRO BV | 2019-11-12 | — | — | CN | disclosed |
| CN-110036493-A | The luminescence component for having the semiconductor light-emitting elements of radiation deep ultraviolet light | 国立研究开发法人情报通信研究机构 | 2019-07-19 | — | — | CN | disclosed |
| CN-108653313-A | Applications of the miR-135a in the drug for preparing treatment myocardial fibrosis | 中国药科大学 | 2018-10-16 | — | — | CN | disclosed |
| CN-107567284-A | Contain the composition that is used to prevent, improve or treat sacred disease of the osmotin peptide as active ingredient | 庆尚大学校产学协力团 | 2018-01-09 | — | — | CN | disclosed |
| CN-107275672-A | It is a kind of containing rubidium and/or the sodium-ion battery electrolysis additive of caesium cation and its application | 上海铷戈科技发展有限公司 | 2017-10-20 | — | — | CN | disclosed |
| CN-102464608-B | Compound and as L-type calcium channel blocker or/and the application of acetylcholinesteraseinhibitors inhibitors | JIANGSU SIMCERE PHARMACEUTICAL RESEARCH COMPANY LIMITED (CN) | 2016-05-11 | — | — | CN | disclosed |
| CN-105481851-A | Hexahydrobenzonaphthyridine-type optically active compound and pharmaceutical use thereof | ZHAOLONG GONG | 2016-04-13 | — | — | CN | disclosed |
| CN-104936596-A | Neuroprotective CB2 receptor agonists | CLEVELAND CLINIC FOUNDATION | 2015-09-23 | — | — | CN | disclosed |
| EP-1664300-A1 | A NEW CLASS OF A2DELTA CALCIUM CHANNEL SUBUNITS | Neuromed Technologies, Inc. (CA) | 2006-06-07 | — | — | EP | disclosed |
| EP-1664301-A1 | NOVEL RAT CALCIUM CHANNEL SUBUNITS AND RELATED PROBES, CELL LINES AND METHODS | Neuromed Technologies, Inc. (CA) | 2006-06-07 | — | — | EP | disclosed |
| US-20060024661-A1 | Modulation of CRF potentiation of NMDA receptor currents via CRF receptor 2 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2006-02-02 | — | — | US | disclosed |
| US-20050095678-A1 | Novel rat calcium channel subunits and related probes, cell lines and methods | ZALICUS PHARMACEUTICALS LTD. (CA) | 2005-05-05 | — | — | US | disclosed |
| US-20050089961-A1 | Class of alpha2delta calcium channel subunits | ZALICUS PHARMACEUTICALS LTD. (CA) | 2005-04-28 | — | — | US | disclosed |
| WO-2005019454-A1 | NOVEL RAT CALCIUM CHANNEL SUBUNITS AND RELATED PROBES, CELL LINES AND METHODS | NEUROMED TECHNOLOGIES, INC. (CA) | 2005-03-03 | — | — | WO | disclosed |
| WO-2005017156-A1 | A NEW CLASS OF α2δ CALCIUM CHANNEL SUBUNITS | NEUROMED TECHNOLOGIES, INC. (CA) | 2005-02-24 | — | — | WO | disclosed |
| CN-1411374-A | Substituted piperazine and piperidine calcium channel blockers | NEUROMED TECH INC (CA) | 2003-04-16 | — | — | CN | disclosed |
| CN-1374294-A | Polyisocyanate containing acyl urea group, its producing process and its application | BAYER AG (DE) | 2002-10-16 | — | — | CN | disclosed |
| US-20020123596-A1 | Polyisocyanates containing acylurea groups, a process for their production and their use | BAYER AKTIENGESELLSCHAFT (DE) | 2002-09-05 | — | — | US | disclosed |